Treatment of lung cancer

Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer

Retrieved on: 
Wednesday, May 17, 2023

SYDNEY, AUSTRALIA, May 17, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that efti, a soluble LAG-3 protein and first-in-class MHC Class II agonist, in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) achieved robust initial Overall Survival (OS) in 1st line non-small cell lung cancer (1L NSCLC) patients in the Phase II TACTI-002 trial.

Key Points: 
  • This immuno-oncology (IO) investigational combination, without the use of chemotherapy, led to excellent initial survival results in the overall intent-to-treat (ITT) 1L NSCLC patient population (N=114), regardless of PD-L1 expression status.
  • We now are showing excellent initial overall survival, which is the gold standard benchmark within oncology, across the entire intent-to-treat population of 1st line NSCLC patients in our Phase II trial.
  • For non-small cell lung cancer patients with >1% PD-L1 expression, a key focus for future development and for which efti in combination with pembrolizumab has Fast Track status, the survival benefit is impressive.
  • Fundamentally, efti is leading to a significant systemic expansion of memory cytotoxic T cells that anti-PD-(L)1 therapies can act upon.

Monte Rosa Therapeutics Presents Preclinical Data from GSPT1 Degrader Program Focused on MYC-Driven Cancers at AACR 2023

Retrieved on: 
Monday, April 17, 2023

The data were presented at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL.

Key Points: 
  • The data were presented at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL.
  • “Our extensive preclinical work on MRT-2359 forms a strong basis for our ongoing clinical trial by providing insight into the effects of GSPT1 degradation on the MYC pathway in cancer.
  • We look forward to reporting initial data from the Phase 1 arm of the trial later this year,” said Owen Wallace, Ph.D., Chief Scientific Officer of Monte Rosa.
  • The preclinical data were presented as follows:
    Title: New Drugs on the Horizon - Discovery of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for MYC-driven cancers
    Session: New Drugs on the Horizon: Part 3
    Title: Development of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for the treatment of lung cancers with MYC-induced translational addiction

Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)

Retrieved on: 
Wednesday, March 29, 2023

TARRYTOWN, N.Y., March 29, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) approved Libtayo® (cemiplimab) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with ≥1% PD-L1 expression. This includes patients that have no EGFR, ALK or ROS1 aberrations and whose tumors are metastatic or locally advanced and not candidates for definitive chemoradiation.

Key Points: 
  • TARRYTOWN, N.Y., March 29, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) approved Libtayo® (cemiplimab) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with ≥1% PD-L1 expression.
  • This marks the fifth approval for Libtayo in Europe.”
    Lung cancer is the leading cause of cancer death worldwide.
  • “This approval highlights continued progress in first-line treatment options for people impacted by advanced lung cancer in Europe.”
    Libtayo is currently approved in the EU and other countries for the treatment of certain patients with advanced basal cell carcinoma (BCC), advanced cutaneous squamous cell carcinoma (CSCC), advanced NSCLC and advanced cervical cancer.
  • The Libtayo combination was also approved by the U.S. Food and Drug Administration (FDA) for advanced NSCLC regardless of PD-L1 expression in November 2022.

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 16, 2023

Initiated patient dosing in October of its Phase 1/2 clinical trial evaluating MRT-2359 for the treatment of MYC-driven solid tumors, including lung cancer.

Key Points: 
  • Initiated patient dosing in October of its Phase 1/2 clinical trial evaluating MRT-2359 for the treatment of MYC-driven solid tumors, including lung cancer.
  • When activated, VAV1 relays a signal cascade that results in immune cell activation and the secretion of several pro-inflammatory cytokines.
  • Net Loss: Net loss for the fourth quarter of 2022 was $30.8 million compared to $23.4 million for the fourth quarter of 2021, and $108.5 million for the year ended December 31, 2022, compared to $74.0 million for the year ended December 31, 2021.
  • Cash Position and Financial Guidance: Cash, cash equivalents, restricted cash, and marketable securities as of December 31, 2022, were $268.1 million, compared to $351.4 million as of December 31, 2021.

Alpha Biopharma Submits New Drug Application for Zorifertinib, a Next-Generation EGFR-TKI to Treat EGFR-mutated NSCLC Patients with CNS Metastases

Retrieved on: 
Monday, January 30, 2023

Due to the low CNS penetration rate of most current lung cancer drugs, lung cancers metastasized to the CNS were poorly controlled and have become one of the leading causes of NSCLC patient deaths.

Key Points: 
  • Due to the low CNS penetration rate of most current lung cancer drugs, lung cancers metastasized to the CNS were poorly controlled and have become one of the leading causes of NSCLC patient deaths.
  • Zorifertinib is a next-generation EGFR-TKI targeting sensitive EGFR mutations (exon 19 deletion and exon 21 L858R) designed for complete blood-brain barrier (BBB) permeability.
  • The EVEREST study was a multinational, multicenter, randomized, open-label, controlled phase II/III clinical trial designed to evaluate the efficacy and safety of Zorifertinib as a first-line treatment for advanced EGFR-mutated NSCLC patients with CNS metastases.
  • We look forward to working closely with the regulatory agencies around the world to bring this innovative treatment option to patients in dire need.

Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Retrieved on: 
Monday, December 12, 2022

CARLSBAD, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that it has received written notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.

Key Points: 
  • CARLSBAD, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that it has received written notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.
  • The letter noted that as a result of the closing bid price of the Company’s common stock having been at least $1.00 per share for a minimum of 10 consecutive business days, the Company has regained compliance with Listing Rule 5550(a)(2) and the matter is now closed.
  • Qualigen Therapeutics, Inc. is a diversified life sciences company focused on developing treatments for adult and pediatric cancer, as well as maintaining and expanding its core FDA-cleared FastPack® System, which has been used successfully in diagnostics for over 20 years.
  • For more information about Qualigen Therapeutics, Inc., please visit www.qualigeninc.com .

Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors

Retrieved on: 
Wednesday, December 7, 2022

The FDA’s response provides Qualigen with clear guidance for formally submitting an IND application for QN-302 after accounting for the agency’s comments and suggestions.

Key Points: 
  • The FDA’s response provides Qualigen with clear guidance for formally submitting an IND application for QN-302 after accounting for the agency’s comments and suggestions.
  • We remain on track to submit the IND application around the first half of 2023,” said Tariq Arshad, M.D., M.B.A., Qualigen’s Chief Medical Officer.
  • The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law.
  • This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

KRAZATI™ (adagrasib) Now Available from Onco360 for the Treatment of Adult Patients with KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Retrieved on: 
Thursday, December 15, 2022

Onco360 is honored to partner with Mirati Therapeutics and become a specialty pharmacy provider for KRAZATI patients, said Benito Fernandez, Chief Commercial Officer, Onco360.

Key Points: 
  • Onco360 is honored to partner with Mirati Therapeutics and become a specialty pharmacy provider for KRAZATI patients, said Benito Fernandez, Chief Commercial Officer, Onco360.
  • We are dedicated to supporting the highly specialized needs of patients battling previously treated, advanced NSCLC with KRAS G12C mutations across the United States.
  • When considering all stages and histologic subtypes of lung cancer, five-year overall survival (OS) is only 22.9%.
  • Unfortunately, 56% of lung cancer patients already have metastatic disease upon initial diagnosis.

ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor

Retrieved on: 
Monday, December 12, 2022

If fully exercised the warrants could result in additional gross proceeds of up to $60 million.

Key Points: 
  • If fully exercised the warrants could result in additional gross proceeds of up to $60 million.
  • The warrants will become immediately exercisable at any time after they are issued and expire two years after the initial issuance date.
  • ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof.
  • ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law.

Lung Cancer Research Foundation Announces 2022 Scientific Research Grant Awards

Retrieved on: 
Tuesday, December 6, 2022

NEW YORK, Dec. 6, 2022 /PRNewswire/ -- The Lung Cancer Research Foundation® (LCRF) is pleased to announce the awardees of its 2022 Scientific Grant Program. This years' grant cycle includes three new areas of funding in addition to its Pilot grants: LCRF Research Grant on Early Detection and Pre-Neoplasia in Lung Cancer, LCRF Research Grants on Oncogenic Drivers in Lung Cancer, and the newly launched LCRF Minority Career Development Award (CDA) for Lung Cancer. In partnership with ALK Positive, a separate request for proposals was introduced for the 2022 funding cycle.

Key Points: 
  • NEW YORK, Dec. 6, 2022 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) is pleased to announce the awardees of its 2022 Scientific Grant Program.
  • This years' grant cycle includes three new areas of funding in addition to its Pilot grants: LCRF Research Grant on Early Detection and Pre-Neoplasia in Lung Cancer, LCRF Research Grants on Oncogenic Drivers in Lung Cancer, and the newly launched LCRF Minority Career Development Award (CDA) for Lung Cancer.
  • "I am honored to receive the William C. Rippe Award for Distinguished Research in Lung Cancer from the Lung Cancer Research Foundation," said Dr. Cocco.
  • LCRF 2022 Grant Award Recipients:
    The 2022 Pilot Grant Program award recipients include:
    The 2022 Minority Career Development Award recipients include:
    The 2022 Research Grant on Early Detection and Pre-Neoplasia in Lung Cancer award recipients include:
    The 2022 Research Grants on Oncogenic Drivers in Lung Cancer award recipients include:
    Swarnali Acharyya, PhD EGFR Resisters grant and James B. Dougherty Award recipient
    Drugging the S100A9-Retinoic acid pathway: companion biomarker and therapy
    The Regents of the University of California, San Francisco
    Emiliano Cocco, PhD MET Crusaders grant and William C. Rippe Award recipient
    The 2022 ALK Positive/Lung Cancer Research Award recipients include:
    For more information about LCRF and the Scientific Grant Program, visit LCRF.org/Research.